The manufacturer of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals voluntarily submitted some of its products for toxicology review and purity testing, including its Gugulipid 40 mesh 2.5 percent extract, Curcumin C3 Complex, Tribulus terrestris 20 percent extract, Indole-3-Carbinol and Triphala extract.
The company's facilities were also audited to ensure they adhere to NSF's good manufacturing practices standards.
Sabinsa president Todd Norton said the decision to submit products for testing was prompted by the FDA's tightening of regulations surrounding dietary supplement ingredients.
"We felt it important to take a proactive stance and work directly with an independent third-party, and in cooperation with our customers, to ensure our ingredients comply to the highest industry safety standards," he said.
The FDA is currently reviewing comments on a proposed rule on current good manufacturing practice requirements for dietary supplements, published in March 2003.
Last November it announced plans to further implement the 1994 Dietary Supplement Health and Education Act (DHSEA) by introducing a regulatory strategy to evaluate safety concerns about dietary ingredients and dietary supplements and producing draft guidance for the industry.